more from Istanbul--Breast cancer group award and start of new trial

[Christine MH-UK]

I think everyone benefits from these big, well-designed, coordinated trials. It helps to make the best use of limited resources.

I do vaguely remember reading somewhere that some scientists had looked at her2 positive cancers and the 70 gene signature and found that her2 cancers overwhelmingly fell in the "needs chemo" category, so it may not change things so much for her2 positive patients. Still, anything that reduces the unnecessary use of chemo is good for patients.